Histogenics Corp (HSGX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Histogenics Corp (HSGX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C6594
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Histogenics Corp (Histogenics) is a regenerative medicine company that develops, markets and commercializes products for musculoskeletal disorders. The company provides product such as neocart, a tissue implant produced using a patient’s own cartilage cells which are harvested from non-weight-bearing cartilage surface of the patient’s femur. It offers products which are used to repair knee cartilage damage. Histogenics provides regenerative medicine platform that combines bioadhesives, cell processing, scaffolding, tissue engineering and growth factors to provide solutions for cartilage injuries associated with bone loss and arthritis. It also offers a platform for tissue repair solutions. Histogenics is headquartered in Waltham, Massachusetts, the US.

Histogenics Corp (HSGX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Histogenics Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Histogenics Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Histogenics Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Histogenics Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Histogenics Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Histogenics Corp, Medical Equipment, Deal Details 10
Venture Financing 10
Histogenics Raises US$10.3 Million In Venture Financing 10
Histogenics Raises US$49 Million In Series A Financing 11
Partnerships 13
Medinet Enters into Licensing Agreement with Histogenics 13
Histogenics Enters into Licensing Agreement with Advanced BioMatrix 14
Histogenics Enters into Licensing Agreement with Koken 15
Equity Offering 16
Histogenics Raises USD17 Million in Public Offering of Shares and Warrants 16
Histogenics Plans to Raise USD75 Million in Public Offering of Securities 18
Histogenics Raises USD6.3 Million in Public Offering of Shares 19
Histogenics Files Registration Statement for Public Offering of Shares to Raise USD50 Million 20
Histogenics Raises USD30 Million in Private Placement of Shares, Series A Preferred Stock and Warrants 21
Histogenics Prices IPO for USD65 Million 22
Histogenics Corp – Key Competitors 24
Histogenics Corp – Key Employees 25
Histogenics Corp – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 09, 2018: Histogenics announces second quarter 2018 financial and operating results 27
May 10, 2018: Histogenics Announces First Quarter 2018 Financial and Operating Results 29
Mar 15, 2018: Histogenics Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017 30
Nov 09, 2017: Histogenics Announces Third Quarter 2017 Financial and Operating Results 33
Aug 10, 2017: Histogenics Announces Second Quarter 2017 Financial and Operating Results 34
May 11, 2017: Histogenics Announces First Quarter 2017 Financial and Operating Results 36
Mar 16, 2017: Histogenics Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016 37
Corporate Communications 39
Jul 31, 2018: Histogenics appoints E. Lynne Kelley, M.D., FACS as chief medical officer 39
Apr 18, 2018: Histogenics Appoints Susan Washer As Board Director 40
Oct 12, 2017: Histogenics Promotes Stephen Kennedy to Executive Vice President & Chief Operating Officer 41
Sep 18, 2017: Histogenics Announces Resignation of CMO 42
Jun 05, 2017: Histogenics Announces the Appointment of Donald Haut, Ph.D. as Chief Business Officer 43
May 15, 2017: Histogenics Receives Innovation Award 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Histogenics Corp, Medical Equipment, Key Facts, 2017 2
Histogenics Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Histogenics Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Histogenics Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Histogenics Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Histogenics Corp, Deals By Market, 2012 to YTD 2018 8
Histogenics Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Histogenics Raises US$10.3 Million In Venture Financing 10
Histogenics Raises US$49 Million In Series A Financing 11
Medinet Enters into Licensing Agreement with Histogenics 13
Histogenics Enters into Licensing Agreement with Advanced BioMatrix 14
Histogenics Enters into Licensing Agreement with Koken 15
Histogenics Raises USD17 Million in Public Offering of Shares and Warrants 16
Histogenics Plans to Raise USD75 Million in Public Offering of Securities 18
Histogenics Raises USD6.3 Million in Public Offering of Shares 19
Histogenics Files Registration Statement for Public Offering of Shares to Raise USD50 Million 20
Histogenics Raises USD30 Million in Private Placement of Shares, Series A Preferred Stock and Warrants 21
Histogenics Prices IPO for USD65 Million 22
Histogenics Corp, Key Competitors 24
Histogenics Corp, Key Employees 25
Histogenics Corp, Subsidiaries 26

List of Figures
Histogenics Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Histogenics Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Histogenics Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Histogenics Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Histogenics Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Histogenics Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Histogenics Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Histogenics Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Histogenics Corp (HSGX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China UnionPay Company Ltd:企業の戦略・SWOT・財務情報
    China UnionPay Company Ltd - Strategy, SWOT and Corporate Finance Report Summary China UnionPay Company Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Cellmid Ltd (CDY)-医療機器分野:企業M&A・提携分析
    Summary Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd is a developer of therapies and diagnostic tests. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such as midkine ELISA kit, advangen international hair …
  • Thales Deutschland GmbH:企業の戦略・SWOT・財務分析
    Thales Deutschland GmbH - Strategy, SWOT and Corporate Finance Report Summary Thales Deutschland GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • transcosmos Inc:企業の戦略・SWOT・財務分析
    transcosmos Inc - Strategy, SWOT and Corporate Finance Report Summary transcosmos Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Analytik Jena AG:企業の戦略的SWOT分析
    Analytik Jena AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Parexel International Corp:企業の戦略的SWOT分析
    Parexel International Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • GenKyoTex SA (GKTX):製薬・医療:M&Aディール及び事業提携情報
    Summary GenKyoTex SA (GenKyoTex), formerly Genticel SA, is a biopharmaceutical company that develops NOX therapies. The company develops targeted NOX inhibitors and molecule therapeutics that inhibit the NOX family of enzymes. GenKyoTex’s lead product candidate, GKT831, a selective NOX1/4 inhibitor, …
  • Sky plc:企業のM&A・事業提携・投資動向
    Sky plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sky plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Sartorius AG (SRT)-医療機器分野:企業M&A・提携分析
    Summary Sartorius AG (Sartorius) manufactures and distributes laboratory and process technology equipment. The company’s lab products portfolio includes laboratory instruments, such as pipettes, laboratory water purification systems, weight sets and lab balances. It provides bioprocess solutions for …
  • Biocartis Group NV (BCART) – Product Pipeline Analysis, 2018 Uate
    Summary Biocartis Group NV (Biocartis) is a molecular diagnostics company that provides personalized medicine for patients through its molecular diagnostics. The company undertakes the development of diagnostics technology platforms for multiplexed detection of bio-analytes, with oncology as its key …
  • Freehold Royalties Ltd (FRU):企業の財務・戦略的SWOT分析
    Summary Freehold Royalties Ltd (Freehold Royalties), formerly Freehold Royalty Trust is an oil and gas company that offers oil and gas operation and financial performance. Its oil and gas assets generate income from natural gas, crude oil, natural gas liquids and potash deposits. It provides horizon …
  • Ampio Pharmaceuticals Inc (AMPE):製薬・医療:M&Aディール及び事業提携情報
    Summary Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by …
  • Mazda Motor Corporation:戦略・SWOT・企業財務分析
    Mazda Motor Corporation - Strategy, SWOT and Corporate Finance Report Summary Mazda Motor Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • R. R. Donnelley & Sons Co (RRD):企業の財務・戦略的SWOT分析
    R. R. Donnelley & Sons Co (RRD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • eHealthInsurance Services Inc:企業の戦略的SWOT分析
    eHealthInsurance Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Coherus BioSciences Inc (CHRS):製薬・医療:M&Aディール及び事業提携情報
    Summary Coherus BioSciences Inc (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used …
  • Sensus USA Inc:企業の戦略的SWOT分析
    Sensus USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Banco Santander SA:企業の戦略・SWOT・財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mineworx Technologies Ltd:企業の戦略・SWOT・財務分析
    Mineworx Technologies Ltd - Strategy, SWOT and Corporate Finance Report Summary Mineworx Technologies Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Arcbest Corp.
    Arcbest Corp. - Strategy, SWOT and Corporate Finance Report Summary Arcbest Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆